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1. Introduction  
Charcot-Marie-Tooth disease (CMT) is the most common inherited neurologic disorder. 
Reportedly 10-28 cases exist per 100,000 in Western societies. CMT patients suffer from a 
variable degree of motor dysfunction which adversely affects locomotion and balance. These 
deficits explain by a slowing of impulse conduction in motor and sensory nerves. This 
affects the recruitment of muscle fibres for contraction whereby slow motor units are 
preferentially affected (Gale et al., 1982; Roy et al., 1996). This results in muscle weakness 
and wasting in the extremities of the body.  
The inefficient propagation of excitatory signals in moto neurons towards peripheral muscle 
in CMT disease is caused by a myelination defect which has a genetic origin. Some 20 genes 
for axon proteins and myelin have been implicated in CMT, and allow the classification into 
specific subtypes of the disease. Frequently affected of these genes are peripheral myelin 
protein 22 (pmp22) and myelin protein zero (MPZ) which are mutated in a majority of cases 
(Braathen et al., 2011). CMT subtype 1A (CMT1A) is the most predominant disease type 
being associated with a duplication of the pmp22 gene (Wise et al., 1993; Magyar et al. 1996). 
The pmp22 gene encodes for a factor that is incorporated into the myelin sheet of neurons 
and is thought to control myelin thickness. The pathology on the CMT1A disease types is 
explained by slowed saltatory transduction in moto neurons due to the aberrant nerve 
insulation (Sereda & Griffiths, 1996). 
Currently there is no cure for CMT. There are however a number of occupational 
interventions that can be used to effectively manage its symptoms 
(http://www.ninds.nih.gov/disorders/charcot_marie_tooth/detail_charcot_marie_tooth.ht
m). The most effective treatment consists of a rehabilitation programs with physical therapy 
as an active ingredient. This involves daily heel cord stretching exercises to prevent Achilles 
tendon shortening. Concomitantly, resistant training of CMT patients can lead to impressive 
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increases in maximal voluntary force (Lindeman et al., 1999). Exercise is thus encouraged 
within each individual patient's capability to condition motor performance in this 
neurological disease. Physical activity however only retards the irreversible degeneration 
and may have detrimental consequences if inappropriately administered (Vinci et al., 2003). 
Gene transfer therapy is a promising route for future cures of muscular disorders. However 
major limitations appear regarding the treatment of neurological diseases such as CMT. In 
this case one would normally expect that the therapy must directly target moto neurons to 
initiate a compensatory mechanism that can correct the missing myelination. This is 
currently not feasible. In this regard the important positive influence of exercise on motor 
performance in CMT patients demands consideration as this may offers an indirect means to 
improve neuromuscular function. This relates to the well established feed forward control of 
the muscle phenotype by muscle use (Fluck & Hoppeler, 2003). It has been pointed out that 
the effects of increased muscle recruitment with exercise involve the promotion of the slow-
oxidative expression program (Schmutz et al., 2010; Baumann et al., 1987). Recently, has 
been established that electrically imposed muscle recruitment can re-establish muscle 
functionality in denervated muscle of tetraplegic patients through the remodelling of the 
contractile and metabolic makeup (Boncompagni et al., 2007). The positive influence of 
exercise in CMT patients suggests that the use-dependent pathway importantly affects 
neuro-muscular function. 
We reasoned that altered muscle use combined with gene therapy for focal adhesion kinase 
(FAK), an enzyme that regulates recruitment dependent slow oxidative gene expression, 
would be a suitable venue to promote pmp22 expression in skeletal muscle. Towards this 
end we investigated the use dependence of pmp22 expression in human skeletal muscle and 
assessed the nature of contractile defects in muscles of a mouse model for CMT at the 
molecular, cellular and functional level. Subsequently we tested whether overexpression of 
FAK can enhance pmp22 expression in skeletal muscle (Durieux et al., 2009).  
2. Methods 
Response to exercise in human muscle - A resting biopsy was collected with a conchotome from 
the non-exercising leg after an overnight fast and prior to exercise. Thereafter, each 
participant performed an acute single-legged endurance exercise bout at 60% of their Pmax 
on an Ergoline bicycle ergometer (Jaeger). There was an incremental warm-up period to 
reach their 60% Pmax, and after 20 minutes of cycling at 80 rpm, the resistance was 
increased by 5 W every 10 seconds until volitional exhaustion. A biopsy was collected with 
the ACECUT needle system (UK Surgical Ltd) from the exercised leg 8 hours after the bout 
of exercise. Biopsy position was standardized based on an ultra-sound measurement at 50% 
of femur length. This study was performed at Manchester Metropolitan University (United 
Kingdom) with permission of the institutional ethics Committee, in compliance with the 
Helsinki Convention for research on human subjects. 
Model of altered muscle activity – Hindlimb suspension of rats was performed for 7 days as 
previously described (Fluck et al., 2005) at the Université Lyon 1 (France) and started 2 days 
after transfection. Subsequent reloading was provoked by allowing the animals to return to 
normal cage activity for 1 or 5 days. 
Hindlimb suspension of mice was performed for 3 days as previously described at the 
University of Berne (Switzerland) (Dapp et al., 2004). This was achieved by attaching the tail 
via a swivel hook to a movable X-Y system; thereby preventing the mouse from touching the 
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ground with its hindlimbs while permitting free movement within the entire cage. Soleus 
muscles were extracted from anesthetized animals (5% isoflurane).  
Animal model of CMT - Pmp22-tg mouse (pmp22tg) as CMT model (strain C3Hb6) were bred 
at the University of Fribourg. The original strain was a gift of U. Suter (University of 
Zurich). The pmp22-tg mice carry approximately 16 and 30 copies of the pmp22 gene and 
display a severe congenital hypomyelinating neuropathy due to the accumulation of 
overexpressed pmp22 in the Golgi compartment, and the concomitant interference with 
myelin assembly during Schwann cell differentiation (Niemann et al., 2000). This is 
characterized by an almost complete lack of myelin and marked slowing of nerve 
conductions (Magyar al., 1996). The animals entering the study were between 1.5- and 3-
month of age.  
Somatic transgenesis for FAK - Gene transfer of pCMV-FAK into soleus muscle of 3-month old 
male Wistar rats was essentially carried out as previously described (Durieux et al., 2009). In 
brief, soleus muscles of anaesthetized rats (60 mg of sodium pentobarbital per kg body) 
were surgically exposed. 70 microgram per 70 microliter of endotoxin-free plasmid in Tris-
EDTA buffer (plasmidfactory, Bielefeld, Germany, www.plasmidfactory.de) was injected in 
the belly portion of the soleus muscle and three trains of 80-pulses of 100 microseconds 
duration, each at 100 mA, were delivered using needle electrodes with the GET42generator 
(Electronique et Informatique du Pilat, Jonzieux, France). The wound was closed with 
sutures and animals transferred to single cages. Right soleus muscles were injected with 
cytomegalovirus promoter-driven plasmids for the constitutive overexpression of chicken 
FAK (pCMV-FAK). The plasmid was a gift from Tony Parsons (University of Virginia, 
Charlottesville, USA). The (left) soleus muscles of the contralateral leg were injected with 
empty pCMV plasmid. 
The experiments were performed at the Universities of Berne (Switzerland) and Lyon 
(France) with the permission of the local Animal Care Committee of the Canton of Berne 
(Switzerland) and following the recommendations provided by the European Convention 
for the protection of Vertebrate Animals used for Experimental and Scientific purposes 
(Strasbourg, 18.III.1986). 
Muscle sampling – Collected muscles were frozen in nitrogen cooled isopentane and stored in 
sealed cryotubes at -80°C until use.  
Transcript profiling – Transcript levels were assessed with microarray in total RNA. In brief, 
25 micrometer cross-sections were prepared for 10 mm3 of muscle volume and total RNA 
extracted with the RNeasy mini-protocol (Qiagen, Basel, Switzerland) for skeletal muscle as 
described (Fluck, Schmutz et al. 2005). Integrity of the RNA was checked with denaturing 
agarose gel electrophoresis, and the concentration was quantified against ribosomal 
standard using the RiboGreen RNA quantification kit (Molecular Probes, Eugene, OR). 
Subsequently RNA was labelled during reverse-transcription and hybridized to different 
platforms dependent on the species:  
For human samples this involved the use of a full human genome Affimetrix platform 
through a commercial provider (DNA vision, Gosselies, Belgium). For statistical analysis 
raw signals were normalized to total mRNA signal on the array and assessed with statistical 
analysis of microarrays between pre and 8-hours post samples with T-tests (SAM). 
For studies with rat and mouse soleus muscle, 3 micrograms of total RNA were reverse 
transcribed with SuperScript II (Life Technologies, Basel, Switzerland) using [-32P]dATP 
and gene-specific primers. Radio-labelled target cDNA was hybridised in ExpressHyb 
solution overnight at 68°C to nylon membranes which spotted cDNA probes (BD 
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Biosciences, Allschwil, Switzerland). The membranes were washed (four times for 1 h in 2x 
SSC (0.3 M sodium chloride, 0.03 M sodium citrate), 1% SDS and once for 30 min in 0.1x 
SSC, 0.5% SDS at 68°C and exposed for 5 days to a phosphoimager (Molecular Dynamics, 
Sunnyvale, CA) for quantification with AIDA Array Easy software (Raytest Schweiz, 
Urdorf, Switzerland).  
For the rat experiment cDNA microarrays (Atlas Rat 1.2, no. 7854; Clontech Laboratories, 
Ozyme, France) were used. More details to this cDNA array can be found on Gene 
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) under GPL153. Data sets 
have been deposited under sample codes GSM10045–GSM10062, and GSM17357–
GSM17361. For statistical analysis, raw signals were normalized to beta actin signal on the 
array and assessed with T-tests. 
For the mouse experiment custom-designed low-density Atlas cDNA expression arrays with 
229 double-spotted probes of mouse cDNAs associated with skeletal muscle form and 
function were employed. More details to this cDNA array can be found on GEO under 
GPL1097. For statistical analysis raw signals were normalized to total mRNA signal on the 
array and assessed with SAM. 
Microscopy - Fibre type analysis of mouse muscle was carried out on cryosections with 
specific antibodies using a two-step detection protocol as described (Fluck et al., 2002). In 
brief, 12 micrometer cryosections were prepared, fixed in cold acetone and wetted in 
phosphate-buffered saline (PBS). Tissue peroxidase activity was then quenched (10 min, 3% 
H2O2 in methanol), sections were washed in PBS and blocked with 3% BSA in PBS for 0.5 h. 
Subsequently the sections were incubated for 1 h at room temperature (20 °C) with 1:100 of a 
monoclonal antibody in 0.3 % BSA/PBS against slow (Chemikon Juro, Lucerne, 
Switzerland) or fast type myosin heavy chain (Sigma Chemicals, (Buchs, Switzerland), 
respectively. Following, 3 brief washing in PBS, the section was reacted for 30 min with 
peroxidase-conjugated goat anti-rabbit IgG (diluted 1:2000 in 0.3 % BSA/PBS; Jackson 
Laboratories, West Grove, PA, USA) and again washed with PBS. Immunoreactivity was 
detected with 3-amino-9-ethylcarbazole substrate (Sigma Chemicals, Buchs, Switzerland); 
the nuclei were counterstained with haematoxylin, and the sections were embedded in 
Aquamount (BDH Laboratory Supplies Poole, UK). The stain was visualised on film 
(Ektachrome 64T, Kodak) using a microscope/photograph system (Vanox-S, Olympus). 
Micrographs were taken from corresponding fields and the fibre types were classified. Slow 
and fast type fibres were differentiated on the basis of the presence of immunoreactivity for 
either type I or type II myosin heavy chain isoforms. Subsequently the percentages of each 
fiber population were counted.  
The overexpression of FAK in muscle fibres was detected out with a Leica TCS SP5 confocal 
microscope on a DMI6000 stage powered by Argon laser and He–Ne lasers (Leica 
Microsystem CMS, Mylton Keynes, UK). In brief, 12 micometer cryosections were reacted 
with a 1 : 100 dilution of rabbit FAK antibody A-17 (Santa Cruz) and MHC2 antibody in 
0.3% BSA in phosphate-buffered saline (PBS) and reacted with fluorescent-labelled 
secondary antibodies (Alexa488-conjugated anti-rabbit IgG, and Alexa555-conjugated anti-
mouse IgG, Molecular Probes/Invitrogen). Sections were embedded in fluorescence-
compatible mounting medium (DAKO, Denmark). Signal for FAK and the co-detected 
myosin protein was inspected with fluorescence after excitation at 458 nm, 476 nm and 488 
nm with sampling in channels between 510–533 nm (Alexa 488) and 593–614 nm (Alexa 555).  
Myography - Soleus muscles were harvested from anesthetized animals (pentobarbital, 50 
microgram/gram body weight) and equilibrated in Tyrod solution (mM/l: 118.0 NaCl, 4.7 
KCl, 2.0 CaCl2, 1.2 MgSO4, 1.1 KH2PO4, 24.0 NaHCO3, 4.5 glucose, pH 7.3–7.4; 5% CO2 / 
95% O2 @ 25°C). Muscles were transferred to Tyrod solution in the contraction chamber, 
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connected to the force transducer (KG7; Muscle tester ORG (SI-Heidelberg, Germany) and 
equilibrated for 5-10 minutes by gazing with 5% CO2 / 95% O2 @ 25°C. Contractions were 
initiated by point stimulation via an Ion Optix myopacer. Signals were recorded using a 
Powerlab system (AD instruments, Germany) and using Chart 5 software. Measurement of 
single twitch, tetanus and fatigue were carried out: First the length of the inserted muscle 
was optimized for maximal force at a stimulation of 1 Hz, 10 V, 0.4 ms. For single twitch 
contractions, the muscle was stimulated at 1 Hz, 10 V, 0.4 ms. For the assessment of fatigue, 
a repeated 3-minute tetanic contraction protocol was used (55/60 Hz, 10 V, 0.4 ms in trains 
of 4 seconds on and off). Fatigue was defined as the contraction cycle when force dropped 
below 50% of original force. Before each measurement the Tyrod solution was exchanged. 
The measured muscles were frozen in liquid nitrogen-cooled isopentane to determine fiber 
size and distribution. Twitch parameters (latency, twitch-time to peak, t1/2 relaxation, 
maximal force) were determined from the digital recording. Measures from contralateral 
muscles were considered as separate biological replica. Statistical analysis was carried out 
with an unpaired t-test (Statistica 6.1). 
2.1 Results 
2.1.1 Regulation of myelin-specific transcripts by muscle activity 
Muscle fibres of anti-gravitational muscles are active for a considerable duration during free 
movement and quiet standing (Hennig & Lomo, 1985). We wished to investigate transcript 
regulation of factors of the myelin sheet by muscle activity. Towards this end we carried out 
an exploratory microarray analysis with the slow oxidative soleus muscle of rats that was 
subjected to changes in muscle activity by hindlimb suspension. The model allows reducing 
load bearing activity to slow oxidative soleus muscle by non-invasive means with the 
suspension of hindlimbs with the option to increase muscle activity with subsequent 
reloading (Morey Holten model as referred by Dapp et al., 2004).  
Transcript profiling of rat soleus muscle showed lowered expression of the myelin-specific 
transcripts, peripheral myelin protein 22 (pmp22), myelin protein zero (MPZ), myelin basic 
protein (mbp) as well as myelin proteolipid protein and myelin-associated glycoprotein 
with reduced muscle activity (Fig. 1). With reloading the abundance of all of these 
transcripts were sizably increased.  
We assessed the response of myelin-specific factors in human knee extensor muscle to 
exhaustive exercise. It has been pointed out before that this exercise stress induces a 
compensatory expression response during the first 24 hours of recovery from exercise 
(Pilegaard et al., 2000; Fluck, 2006). The analysis in the mixed vastus lateralis muscle 
consolidated the observation on the regulation of myelin-specific transcripts by muscle use. 
Pmp22, mpz and mbp transcript levels were increased by 1.2 to 1.8-fold (table 1). 
 
gene abbr mean SE p-value 
myelin basic protein MBP 1.7 0.3 2% 
myelin expression factor 2 MYEF2 1.4 0.2 3% 
peripheral myelin protein 22 PMP22 1.8 0.4 5% 
myelin associated glycoprotein MAG 1.1 0.1 5% 
myelin protein zero MPZ 1.2 0.1 21% 
myelin oligodendrocyte glycoprotein MOG 1.2 0.1 25% 
Table 1. Expressional alterations in myelin-specific transcripts in human vastus lateralis 
muscle after endurance exercise.  
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Fig. 1. Expression of myelin-specific transcripts depends on muscle activity. Bar graphs 
indicating mean ± standard error (SE) of level changes of five transcripts (per beta actin) in 
rat m. soleus with 7 days of hindlimb suspension vs. cage controls (A) and one day of 
reloading vs. hindlimb suspension (B). Asterisks denote significant effect based on a T-test. 
n=6. The line of identity is given. Abbreviations: mpz, myelin protein zero; pmp22, 
peripheral myelin protein 22; plp, myelin proteolipid protein; mag, myelin-associated 
glycoprotein; mbp, myelin basic protein. 
2.2 Contractile defects in a mouse model of pmp22-dependent CMT 
Pmp22-tg mice show reduced pmp22 protein expression, lack myelination, and demonstrate 
neurogenic muscle atrophy (Magyar et al., 1996).  
We compared the muscles of pmp22-tg mice vs. strain matched controls to identify 
contractile defects with pmp22-dependent moto neuron aberration. Soleus muscle of 
pmp22-tg mice demonstrated a shift towards an atrophic, slow phenotype. This was 
indicated by the reduced muscle weight (Fig. 2D) and elevated percentage of slow type 
muscle fibres (Fig. 2A-C). This became manifest in prolonged time-to-peak and half time of 
muscle relaxation (Fig. 2D). The aberrations resulted in a reduction in RNA messengers for 
the slow oxidative expression program concomitantly with the elevated abundance of gene 
transcripts for fast type myogenesis (Fig. 3). The only exceptions were GAPDH and CA3 
being involved in pH regulation of slow type muscle fibres.  
2.3 Aberrant muscle plasticity in CMT mice with altered muscle use 
Towards understanding the functional implication of motor unit recruitment for control of 
muscle gene expression we subjected pmp22-tg mice to 3 days of hindlimb suspension. 
Microarray experiments identified important alterations in transcript expression in soleus 
muscles with 3 days of reduced muscle activity (Fig. 4). The differences between suspended 
and cage control muscle distinguished between wildtype and pmp22-tg mice. This 
concerned gene ontologies defining the contractile and metabolic muscle phenotype of 
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Fig. 2. Contractile aberrations in anti-gravitational muscle of pmp22-transgenic mice. A, B) 
Micrographs visualizing cross sections of soleus muscle from a wildtype (A) and pmp22-tg 
mouse (B) after staining for slow type myosin heavy chain. C, D) Bar graphs indicating 
mean ± SE of percentage of slow type muscle fibres (C) in soleus muscle and weight (D) of 
wildtype (white bar, n=5) and pmp22-transgenic mice (black bar, n=6). E) Mean ± SE and 
standard deviation (SD) of contractile parameters in soleus muscles of wildtype (n=6) and 
pmp22-transgenic mice (n=5). Asterisks denote significant effect based on a T-test. 
skeletal muscle. Thereby transcript levels of factors of myogenesis, fast contraction, 
glycolysis and oxidative metabolism altered in opposite ways between wildtype and 
pmp22-tg muscle. 
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Fig. 3. Aberrant transcript expression in pmp22-transgenic mice. Bar graphs representing the 
mean fold difference in transcript levels between pmp22tg and wildtype mice for gene 
ontologies which set the phenotype of soleus muscle. Data were generated with custom 
mircrarrays for 229 selected factors, normalized to total mRNA and assessed with unpaired 
test using SAM (n=4). Black and grey bars denote significantly up-regulated and 
significantly down-regulated transcripts, respectively. Transcripts reflected by white bars 
were not significant altered. The line of identity is given. Abbreviations: Glut2, facilitative 
glucose transporter member 2; LDH2, lactate dehydrogenase 2; GAPDH; glyceraldehyde-3-
phosphate dehydrogenase; COX IVa, cytochrome c oxidase subunit 4 isoform 1; COX Vb, 
cytochrome c oxidase subunit 5B; COX VIa2; cytochrome c oxidase subunit 6a2; CPTI, 
carnitine O-palmitoyltransferase 1; FAT/CD36, cluster of Differentiation 36/Fatty acid 
transport protein; HADH, 3-hydroxyacyl-CoA dehydrogenase; H-FABP; fatty acid binding 
protein of the heart; LPL, lipoprotein lipase; MCAD, medium-chain specific acyl-CoA 
dehydrogenase; MHC I; myosin heavy chain type I; MHC IIA; myosin heavy chain type IIA; 
MHC IIB; myosin heavy chain type IIB; MHC IIX, myosin heavy chain type IIX; IGF-I, 
Insulin-like growth factor I; SRF, serum response factor; Rb, retinoblastoma-associated 
protein; myoD, Myoblast determination protein 1; p21, cyclin-dependent kinase inhibitor 1; 
myf6/herculin; myogenic factor 6. 
2.4 Muscle-targeted overexpression of the mechano-sensor FAK elevates myelin 
factor expression 
We assessed whether overexpression of the governor of slow-oxidative gene expression, 
focal adhesion kinase (FAK), can control myelin factor expression and pmp22-dependent 
gene transcripts. Using gene electro transfer we introduced a constitutively active 
expression plasmid for FAK, pCMV-FAK, in soleus muscle of the right leg of Wistar rats. 
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Transfection of the contralateral muscle with empty pCMV plasmid served as intra-animal 
control. Immunofluorescence experiments showed that overexpression of FAK was confined 
to muscle fibres but was not observed in contralateral controls (Fig. 5). Microarray analysis 
demonstrated that FAK overexpression increased transcript levels of pmp22 along with the 
one of MBP in soleus muscle of active rats. Concurrently the expression of a battery of slow 
oxidative genes was increased (Durieux et al., 2009). 
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Fig. 4. Anomalous expression response of pmp22-transgenic mice to reduced muscle 
activity. Bar graph representing the mean fold difference in transcript levels in soleus 
muscle between wildtype mice (A, n=8) and pmp22tg (A, n=4) with 3 days of reduced load 
bearing (suspension) vs. cage controls. Data were generated with custom microarrays for 
229 selected factors, normalized to total mRNA and assessed with a paired test between 
values from suspended and cage control muscle using SAM. Black and grey bars denote 
significantly up-regulated and significantly down-regulated transcripts, respectively. 
Transcripts reflected by white bars were not significant altered. The line of identity is given.  
Abbreviations: Glut 4, facilitative glucose transporter member 4; IGF-BP5, Insulin-like 
growth factor binding protein 5. For others consult legend to figure 3. 
2.5 FAK dependent elevation of pmp22 expression is use dependent  
FAK signals mechanical stimuli in muscle to gene expression and protein synthesis (Durieux 
et al. 2009; Klossner et al., 2009). We subjected the FAK-transfected soleus muscles to 7 days 
of hindlimb suspension and subsequent one day of reloading to assess the interaction of 
muscle activity with gene therapy. Pmp22 transcript expression was little affected by 
reduced load bearing. With subsequent reloading however pmp22 levels were reduced. This 
effect was transient and was gone 5 days after reloading 
3. Discussion 
Skeletal muscle is the largest tissue of vertebrate species and most muscle groups rely on 
muscle activity to maintain their phenotype (Booth & Thomason, 1991). This is most 
pronounced in slow oxidative muscle types which are typically involved in control of gait 
and posture (Roy et al., 1996). This resembles the preferential affection of oxidative muscles 
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Fig. 5. FAK driven expression of myelination factors is dependent on muscle activity. A) 
Representative micrograph from a cryosections of a pCMV-FAK transfected soleus muscle 
of a rat after double staining for FAK (red) and fast type myosin heavy chain (MHC, yellow) 
as recorded with a confocal microscope. B) Bar graph representing the mean difference + SE 
of transcripts for three myelination factors pmp22, mpz and mbp between pCMV-FAK vs. 
empty (pCMV) transfected soleus muscle. Black, white and grey bars reflect data from cage 
controls, 7 days suspended and one day reloaded mice. Asterisks denote significant effect 
based on a T-test. 
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Fig. 6. Implication of excitation-transcription coupling in muscle control. Sketch summarizes 
a concept whereby moto neuron excitation (feed forward) with muscle use triggers the 
expression of myelination factors which exert feedback control on the muscle-nerve 
interaction. 
in the trembler model of CMT disease (Gale et al., 1982). This use-dependent control of gene 
expression and protein synthesis (Fluck & Hoppeler, 2003; Wilkinson et al., 2008) is not 
taken into consideration in current gene therapy of neurological muscle disorders. 
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Here we prove the concept that muscle fibre targeted somatic transgenesis can affect nerve-
related gene expression. The results point out that muscle activity importantly modifies the 
pre-translational effects of the somatic overexpression of the governor of the slow oxidative 
muscle program, FAK, on the expression of myelin-specific transcripts. This was shown by a 
similar regulation of pmp22, MPZ and MBP transcripts by muscle disuse with reduced load-
bearing (down-regulation) in rats, increased load-bearing muscle activity in rats and with 
endurance exercise (up-regulation) in man (table 1, Fig. 1). The direction of the transcript 
levels points out that that myelin-specific transcript expression is related to fibre 
recruitment. Such a mutual control of the muscle-nerve interaction is known from the action 
of neurotrophic factors during normal development of the slow muscle fiber phenotype 
(Carrasco & English, 2003). These findings support the novel concept that in addition to feed 
forward control of muscle gene expression by muscle use (Calvo et al., 2001) a feedback 
mechanism exists whereby muscle activity in return regulates moto neurons (Fig. 6). 
The functional consequences of use dependent expressional alterations in myelin sheet-
specific factors in skeletal muscle remain to be explored. Pmp22 is a major component of 
myelin expressed in the compact portion of essentially all myelinated fibres in the 
peripheral nervous system and is produced predominantly by Schwann cells. Pmp22 is 
expressed in cranial nerves but not in the mature central nervous system. Studies in injured 
nerve suggested a role during Schwann cell growth and differentiation and maturation of 
the neuromuscular junction (Spreyer et al., 1991; Patel et al., 1992; Magyar et al., 1996). 
Interestingly the identified transcript level changes in our study are in line with the 
degeneration of NMJ with disuse (Deschenes et al., 2001) and neurological adaptation which 
improves fibre recruitment early with exercise (Roy et al., 1996). This supports a hypothesis 
whereby elevated myelin-specific transcript expression may allow the preservation and 
improvement of neuromuscular control of muscle fibres. 
Previous examinations of soleus and EDL muscle in the trembler mouse model of CMT 
revealed that the deep/oxidative and soleus muscles are particularly affected by CMT but 
fibre type differences were not described (Gale et al., 1982). Our measures in the pmp22-tg 
model of CMT emphasize that in addition to altered muscle contractility, slow fibre size and 
transcript expression in the anti-gravitational muscle, m. soleus, is anomalous. The 
reduction in RNA messengers for the slow oxidative expression program (Fig. 3) is possibly 
explained by volumetric alterations in fibre size as suggested by visually larger CSA ratio 
between fast and slow type fibres reflecting atrophy of slow type fibres. Smaller type I fibres 
in animal models for pmp22-dependent motor and sensory neuropathy type has been noted 
before (Schuierer et al., 2005). This would increase the contribution of transcripts in fast type 
muscle fibres. The concomitantly elevated abundance of transcripts for fast type myogenesis 
between pmp22-tg and wildtype mice likely reflects altered regulation in fast muscle fibres 
(Deschenes et al., 2001).  
A main finding of our investigation was that differences between pmp22 and wildtype mice 
were preserved in an ‘opposite’ transcript response of soleus muscle to reduced load-
bearing. Altered transcript expression is a potentially important indicator of pathological 
changes with reduced muscle activity (Bey et al. 2003; Chen et al., 2007). In this regard it is 
important that the response of soleus muscle from wildtype mice to 3 days of unloading 
reproduced the changes reported in a different mouse strain after 7 days of reduced load-
bearing (Dapp, Schmutz et al. 2004). This overlap concerned contractile (MHCIIB) and 
metabolic factors (COXVb, COXVIa2, LDH2). Exceptions concerned those involved in 
myogenesis which were not altered after 3 days in this study. Strikingly, the transcript 
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response of soleus muscle of pmp22-tg mice to suspension “mirrored” the differences seen 
between the pmp22-tg mice and wildtype mice at baseline. These observations imply the 
existence of use-dependent mechanism that “inverts” expression responses in model of 
CMT.  
This observation relates to the effects of current occupational therapy by exercise. We have 
shown before that FAK overexpression controls contractile performance of soleus muscle in 
a activity-dependent manner via the regulation of transcript expression (Durieux et al., 
2009). Intriguingly with FAK overexpression and the resumption of loading bearing muscle 
activity, the transcript level of myelination factors were reduced compared to controls (Fig. 
5). Our previous findings in the suspension model show that reduced myogenic factor RNA 
expression after 24 hours of the reloading stimulus is related to a concomitant increase is the 
encoded protein (Fluck et al., 2008). This relates to the observation that FAK acts as a 
molecular switch for transition between anabolic and catabolic reactions in skeletal muscle 
and controls the protein synthetic pathway via p70S6K (Durieux et al., 2009; Klossner et al., 
2009) . This suggests that transcript level changes in the early phase of reloading may reflect 
inverse alterations in protein synthesis. These relationships imply that the ’muscle activity’ 
is a confounding variable which would be valuable to be considered in somatic gene 
therapy of skeletal muscle. The fact that activity dependent gene regulation is reflected by 
the mechano-regulation of FAK activity by pTyr-397 phosphorylation (Durieux et al., 2009) 
indicates possible venues to stimulate this directly in situations where muscle activity is not 
an option.  
The extent to which differences between slow and fast motor neurons are involved in the 
coupling between muscle excitation and gene expression (excitation-transcription coupling) 
is currently not well understood (Schiaffino & Serrano, 2002; Wakeling & Syme, 2002). Based 
on a preferential atrophy of slow type muscle fibres (Roy et al., 1996; Dapp et al., 2004), 
hindlimb suspension is expected to affect slow motor units more that fast type units. Our 
findings on the distinction of basal and disuse-induced transcript expression with slowed 
signal propagation down the motoneuron (Magyar et al., 1996) highlight the importance of 
correct excitation for control of gene expression (Calvo et al., 2001). 
4. Conclusion  
Our observations indicate that muscle dysfunction with Charcot-Marie-Tooth (CMT) is not 
due to a single, central mechanism. A novel, contraction-dependent feedback mechanism is 
identified that controls myelin-specific transcripts via a muscle fibre-related pathway. 
Somatic transfection of muscle fibres with the mechanosensor FAK prove the concept that 
pmp22 expression which is lowered in CMT can be stimulated when combined with skeletal 
muscle use. This indicates that muscle activity is a confounding variable that warrants 
exploration in future gene therapeutic strategies to treat and manage neuromuscular 
disease.  
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